Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas De Raedt

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|April 2, 2026
Identification of CD74-positive antigen presenting glioma cells in primary human tumors and murine models of NF1 high-grade gliomaStephanie N Brosius, Jonathan H Sussman, Isabella A DiStefano, et al.
Genes, Chromosomes & Cancer|July 11, 2006
Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patientsThomas De Raedt, Ophélia Maertens, Magdalena Chmara, et al.
Nature Genetics|November 23, 2006
Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletionThomas De Raedt, Matthew Stephens, Ine Heyns, et al.
Human Molecular Genetics|February 8, 2006
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patientsOphélia Maertens, Hans Prenen, Maria Debiec-Rychter, et al.
Nature|August 15, 2014
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapiesThomas De Raedt, Eline Beert, Eric Pasmant, et al.
Cancer Research|October 11, 2017
A Collaborative Model for Accelerating the Discovery and Translation of Cancer TherapiesOphélia Maertens, Mila E McCurrach, Benjamin S Braun, et al.
Cancer Discovery|December 16, 2016
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast CancersSarah Naomi Olsen, Ania Wronski, Zafira Castaño, et al.
Nature Medicine|February 16, 2010
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaBJunxia Min, Alexander Zaslavsky, Giuseppe Fedele, et al.
Sarcoma|February 25, 2020
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)AeRang Kim, Yao Lu, Scott H Okuno, et al.
Cancer Cell|April 4, 2020
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung CancersStephanie L Guerra, Ophélia Maertens, Ryan Kuzmickas, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|April 2, 2026
Identification of CD74-positive antigen presenting glioma cells in primary human tumors and murine models of NF1 high-grade gliomaStephanie N Brosius, Jonathan H Sussman, Isabella A DiStefano, et al.
Genes, Chromosomes & Cancer|July 11, 2006
Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patientsThomas De Raedt, Ophélia Maertens, Magdalena Chmara, et al.
Nature Genetics|November 23, 2006
Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletionThomas De Raedt, Matthew Stephens, Ine Heyns, et al.
Human Molecular Genetics|February 8, 2006
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patientsOphélia Maertens, Hans Prenen, Maria Debiec-Rychter, et al.
Nature|August 15, 2014
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapiesThomas De Raedt, Eline Beert, Eric Pasmant, et al.
Cancer Research|October 11, 2017
A Collaborative Model for Accelerating the Discovery and Translation of Cancer TherapiesOphélia Maertens, Mila E McCurrach, Benjamin S Braun, et al.
Cancer Discovery|December 16, 2016
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast CancersSarah Naomi Olsen, Ania Wronski, Zafira Castaño, et al.
Nature Medicine|February 16, 2010
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaBJunxia Min, Alexander Zaslavsky, Giuseppe Fedele, et al.
Sarcoma|February 25, 2020
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)AeRang Kim, Yao Lu, Scott H Okuno, et al.
Cancer Cell|April 4, 2020
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung CancersStephanie L Guerra, Ophélia Maertens, Ryan Kuzmickas, et al.
Pageof 4